Literature DB >> 17850358

The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.

Beverley A Shannon1, Ronald J Cohen, Kerryn L Garrett.   

Abstract

OBJECTIVE: To investigate whether the serum titres of Propionibacterium acnes antibodies in patients undergoing prostate biopsy are associated with prostate cancer or markers of prostate disease, including serum prostate-specific antigen (PSA) levels. PATIENTS AND METHODS: The cell wall-associated proteins from P. acnes types IA, IB and II were extracted and characterized by Western blotting and immunoblotting. We developed an enzyme-linked immunosorbent assay (ELISA) based on extracted proteins to determine the anti-P. acnes antibody titres in the sera of 68 patients undergoing prostate biopsy. Correlations between these titres and multiple markers of prostate disease were investigated.
RESULTS: In patients with biopsies negative for cancer, a high anti-P. acnes antibody titre was associated with high serum PSA levels (>or=10.0 ng/mL, P = 0.04), and multiple linear regression analysis identified antibody titre as the predominant independent predictor of serum PSA level (P = 0.03). The titre was positively correlated with patient age, prostate volume and aggressive inflammation, suggesting an involvement with benign prostatic hyperplasia (BPH). However in patients with histologically detected cancer, the volume of cancer in the biopsy cores was the predominant independent predictor of serum PSA (P = 0.01).
CONCLUSIONS: These results support our hypothesis that P. acnes might be involved in the development of inflammation-related prostate diseases, in particular with BPH. Our ELISA might be valuable for identifying P. acnes infection of the prostate gland in patients with elevated serum PSA levels but a negative biopsy, and might identify men at risk of developing clinical BPH. However, an investigation with more patients is needed to confirm these preliminary findings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850358     DOI: 10.1111/j.1464-410X.2007.07214.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

Review 1.  Role of bacteria in oncogenesis.

Authors:  Alicia H Chang; Julie Parsonnet
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

2.  Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case-control study.

Authors:  G Severi; B A Shannon; H N Hoang; L Baglietto; D R English; J L Hopper; J Pedersen; M C Southey; R Sinclair; R J Cohen; G G Giles
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

Review 3.  Inflammation and prostate cancer: a focus on infections.

Authors:  Siobhan Sutcliffe; Elizabeth A Platz
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

Review 4.  Bacteria-Mediated Oncogenesis and the Underlying Molecular Intricacies: What We Know So Far.

Authors:  Shashanka K Prasad; Smitha Bhat; Dharini Shashank; Akshatha C R; Sindhu R; Pornchai Rachtanapun; Devananda Devegowda; Prasanna K Santhekadur; Sarana Rose Sommano
Journal:  Front Oncol       Date:  2022-04-04       Impact factor: 5.738

5.  Chronic prostatic infection and inflammation by Propionibacterium acnes in a rat prostate infection model.

Authors:  Jan Olsson; Johanna Bergh Drott; Lovisa Laurantzon; Oscar Laurantzon; Anders Bergh; Fredrik Elgh
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

6.  Quantification of the antibody response to Propionibacterium acnes in a patient with prosthetic valve endocarditis: - a case report.

Authors:  T Herren; M A Middendorp; R Zbinden
Journal:  BMC Infect Dis       Date:  2016-04-29       Impact factor: 3.090

7.  Platelet activation and aggregation by the opportunistic pathogen Cutibacterium (Propionibacterium) acnes.

Authors:  Frida Petersson; Ola Kilsgård; Oonagh Shannon; Rolf Lood
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.